Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1.

Int J Mol Sci · 2021 · PMC8468664 · PMID 34576016

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These trials enrolled high-risk T2DM patients and showed that SGLT2 inhibitors only slightly reduce major adverse cardiovascular events (MACE), but all trials reported a highly significant ~32% relative reduction in risk of hospitalization for HF with no heterogeneity [ 16 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.